Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis

被引:112
作者
Loven, K [1 ]
Stein, L
Furst, K
Levy, S
机构
[1] Rivergate Dermatol & Skin Care Ctr, Goodlettsville, TN USA
[2] Henry Ford Hosp, Detroit, MI USA
[3] Dermik Labs, Berwyn, PA USA
关键词
fluorouracil; actinic keratosis; tolerability; facial irritation; efficacy; patient satisfaction;
D O I
10.1016/S0149-2918(02)80012-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: A new 0.5% fluorouracil cream has been developed that provides an alternative to the more highly concentrated topical formulations of fluorouracil that are currently available. Objective: This was a comparison of the tolerability and efficacy of the 0.5% and 5% fluorouracil creams in the treatment of actinic keratosis (AK). Methods: During this single-blind, randomized study, patients with greater than or equal to6 AK lesions were treated for 4 weeks with the 0.5% (once daily) and 5% (twice daily) fluorouracil creams applied to opposite sides of the face. After the end of treatment, patients were followed for an additional 4 weeks. Efficacy variables included absolute and percent reductions in AK lesions from baseline and total clearance of AK lesions. A questionnaire was used to evaluate patients' treatment preferences. Tolerability was evaluated through continuous monitoring of adverse events. Results: Treatment with 0.5% fluorouracil cream reduced the number of AK lesions from 11.3 at baseline to 2.5 at the end of the 4-week follow-up phase, compared with a reduction from 10.3 to 4.2 lesions after treatment with 5% fluorouracil cream. The reduction was significantly greater with the 0.5% cream compared with the 5% cream (P = 0.044). The 0.5% cream was as effective as the 5% cream in terms of the percent reduction in AK lesions from baseline (67% and 47%, respectively) and in achieving total clearance of AK lesions (both treatments, similar to43% of patients). Both treatments were associated with similar degrees of investigator-rated irritation;, however, patients preferred the 0.5% cream because they felt it was more tolerable (P = 0.003), easier to apply, and had a once-daily application schedule. Although all patients experienced facial irritation in association with both creams, fewer patients treated with the 0.5% cream reported symptoms of facial irritation. Conclusions: In this study, 0.5% fluorouracil cream once daily was at least as effective as 5% fluorouracil cream twice daily in terms of the percent reduction in AK lesions and total clearance of AK lesions; it was more effective than the 5% cream in reducing the absolute number of AK lesions from baseline. Patients preferred the 0.5% cream to the 5% cream.
引用
收藏
页码:990 / 1000
页数:11
相关论文
共 13 条
[1]  
[Anonymous], J GERIATRIC DERMATOL
[2]   NONINFLAMMATORY DESTRUCTION OF ACTINIC KERATOSES BY FLUOROURACIL [J].
BREZA, T ;
TAYLOR, JR ;
EAGLESTEIN, WH .
ARCHIVES OF DERMATOLOGY, 1976, 112 (09) :1256-1258
[3]   SELECTIVE CYTO-TOXIC EFFECT OF TOPICAL 5-FLUOROURACIL (REPRINTED) [J].
DILLAHA, CJ ;
JANSEN, GT ;
HONEYCUTT, WM ;
BRADFORD, AC .
ARCHIVES OF DERMATOLOGY, 1983, 119 (09) :774-783
[4]   SKIN CHANGES IN PATIENTS TREATED WITH 5-FLUOROURACIL [J].
FALKSON, G ;
SCHULZ, EJ .
BRITISH JOURNAL OF DERMATOLOGY, 1962, 74 (06) :229-236
[5]   EFFECT OF TOPICAL 5-FLUOROURACIL TREATMENT ON ACTINIC KERATOSIS - LIGHT AND ELECTRON-MICROSCOPIC STUDY [J].
HODGE, SJ ;
SCHRODT, GR ;
OWEN, LG .
JOURNAL OF CUTANEOUS PATHOLOGY, 1974, 1 (06) :238-248
[6]  
JEGASOTHY SM, 2001, SKIN AGING S, P4
[7]  
JORIZZO J, 2001, SKIN AGING, P4
[8]  
JORIZZO J, 2001, ANN M AM AC DERM MAR
[9]   A COMPARISON OF THE EFFICACY AND SAFETY OF JESSNERS SOLUTION AND 35-PERCENT TRICHLOROACETIC-ACID VS 5-PERCENT FLUOROURACIL IN THE TREATMENT OF WIDESPREAD FACIAL ACTINIC KERATOSES [J].
LAWRENCE, N ;
COX, SE ;
COCKERELL, CJ ;
FREEMAN, RG ;
CRUZ, PD .
ARCHIVES OF DERMATOLOGY, 1995, 131 (02) :176-181
[10]   A pharmacokinetic evaluation of 0.5% and 5% fluorouracil topical cream in patients with actinic keratosis [J].
Levy, S ;
Furst, K ;
Chern, W .
CLINICAL THERAPEUTICS, 2001, 23 (06) :908-920